Suggestions
Ami Fadia
Managing Director, Senior Biotech Equity Research Analyst at Needham & Company
Who is Ami Fadia?
Ami Fadia is a Managing Director and Senior Biotech Equity Research Analyst at Needham & Company, a New York-based investment bank and asset management firm.12 She joined Needham in May 2021 and covers the biotechnology sector with a focus on targeted oncology and neuroscience.23
Prior to joining Needham, Fadia spent four years as a Managing Director and Senior Analyst at SVB Leerink. She also worked at UBS for six years, most recently as a Senior Analyst.2 Additionally, Fadia has industry experience, having served as Head of Strategy & Operations at Sandoz, where she built a team responsible for strategic planning, sales force strategy, training, project management, budgeting, and business development.2
Fadia began her career in consulting at KPMG and McKinsey & Company, working in their healthcare practices.2 She holds an MBA from the Kellogg School of Management and a Bachelor's of Commerce from Shri Ram College, Delhi University. Fadia is also a member of the Institute of Chartered Accountants of India.2
As of September 2024, Fadia has a 3.86-star rating as a Wall Street Analyst on TipRanks, with a 47.66% success rate covering 54 stocks.1 Her most profitable rating was a Buy recommendation on Avadel Pharmaceuticals (AVDL) with a 541.20% return.1
